Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 16;145(3):253-255.
doi: 10.1182/blood.2024027065.

Is it time to screen for multiple myeloma?

Irene M Ghobrial  1 , Floris Chabrun  1
Affiliations

Is it time to screen for multiple myeloma?

Irene M Ghobrial et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: I.M.G. reports consulting/advisory roles at AbbVie, Adaptive, Amgen, Aptitude Health, Bristol Myers Squibb, GlaxoSmithKline, Huron Consulting, Janssen, Menarini Silicon Biosystems, Oncopeptides, Pfizer, Sanofi, Sognef, Takeda, Binding Site a part of Thermo Fisher Scientific, Window Therapeutics, and 10× Genomics; speaker fees from Vor Biopharma and Veeva Systems, Inc., and is a cofounder and holds private equity in PreDICTA Bioscience. I.M.G.’s spouse is the Chief Medical Officer and holds private equity in Disc Medicine. F.C. declares no competing financial interests.

Comment on

References

    1. Visram A, Larson D, Norman A, et al. Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection. Blood. 2025;145(3):325–333. - PubMed
    1. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–5417. - PMC - PubMed
    1. Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–1127. - PMC - PubMed
    1. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–1369. - PubMed
    1. Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) Blood Cancer J. 2020 Oct 16;10(10):102. - PMC - PubMed

LinkOut - more resources